Abstract
Oligodendrogliomas account for a small subset of all gliomas, but they often are more sensitive to treatment than other glioma subtypes. In addition, oligodendrogliomas are the first central nervous system neoplasm for which a specific molecular abnormality, allelic loss of 1p/19q (1p/19q loss), correlates with patient outcome in large-scale prospective clinical trials. However, the incorporation of 1p/19q status into clinical practice remains controversial. Other molecular alterations found in oligodendrogliomas include hypermethylation of the promoter for the MGMT gene, TP53 mutations, EGFR and platelet-derived growth factor/PDGFR alterations, and 9p and 10q loss.
MeSH terms
-
Alleles
-
Brain Neoplasms / diagnosis*
-
Brain Neoplasms / genetics*
-
Brain Neoplasms / therapy*
-
Chromosome Deletion
-
Chromosome Mapping
-
Chromosomes, Human, Pair 1 / genetics
-
Chromosomes, Human, Pair 19 / genetics
-
DNA Methylation
-
ErbB Receptors / metabolism
-
Genes, p53
-
Humans
-
Mutation
-
Oligodendroglioma / diagnosis*
-
Oligodendroglioma / genetics*
-
Oligodendroglioma / therapy*
-
Platelet-Derived Growth Factor / genetics
-
Platelet-Derived Growth Factor / metabolism
-
Prognosis
-
Receptors, Platelet-Derived Growth Factor / genetics
-
Tumor Suppressor Protein p53 / genetics
Substances
-
Platelet-Derived Growth Factor
-
TP53 protein, human
-
Tumor Suppressor Protein p53
-
ErbB Receptors
-
Receptors, Platelet-Derived Growth Factor